子宫肉瘤治疗新进展

摘要

Uterine sarcoma is a rare uterine malignant tumor with a high grade of malignancy and pool prognosis,which is easy to have local recurrence and distant metastasis.Surgery as the main treatment,emphasizes the standardization and individuation.Postoperative radiation treatment does not improve both disease-free survival rate and overall survival rate of uterine leiomyosarcomas patients.Adjuvant chemotherapy can improve overall survival rate of carcinosarcomas patients,therefore it is considered as the standard of therapeutic regimen.Trabectedin has demonstrated effective and reasonably safe for patients with advanced uterine leiomyosarcomas.The medical target therapy of uterine sarcoma is still at the exploratory stage.%子宫肉瘤是一种少见的子宫恶性肿瘤,恶性程度高,易局部复发及远处转移,预后不佳.手术为主要的治疗方法,强调术后治疗的规范化及个体化.术后放射治疗并不能改善子宫平滑肌肉瘤患者的无瘤生存率和整体生存率,辅助性化疗因能提高子宫癌肉瘤患者的整体生存率而成为标准治疗方案.曲贝替定用于治疗晚期子宫平滑肌肉瘤有效且安全.靶向药物治疗子宫肉瘤仍处于研究探索阶段.